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ABSTRACT
Breast cancer (BC) is one of the major causes of cancer death in women and 
is closely related to hormonal dysregulation. Estrogen receptor (ER)-positive BCs 
are generally treated with anti hormone therapy using antiestrogens or aromatase 
inhibitors. However, BC cells may become resistant to endocrine therapy, a process 
facilitated by autophagy, which may either promote or suppress tumor expansion. 
The autophagy facilitator HSPB8 has been found overexpressed in some BC. Here 
we found that HSPB8 is highly expressed and differentially modulated by natural or 
synthetic selective ER modulators (SERMs), in the triple-positive hormone-sensitive 
BC (MCF-7) cells, but not in triple-negative MDA-MB-231 BC cells. Specific SERMs 
induced MCF-7 cells proliferation in a HSPB8 dependent manner whereas, did not 
modify MDA-MB-231 cell growth. ER expression was unaffected in HSPB8-depleted 
MCF-7 cells. HSPB8 over-expression did not alter the distribution of MCF-7 cells in the 
various phases of the cell cycle. Conversely and intriguingly, HSPB8 downregulation 
resulted in an increased number of cells resting in the G0/G1 phase, thus possibly 
reducing the ability of the cells to pass through the restriction point. In addition, 
HSPB8 downregulation reduced the migratory ability of MCF-7 cells. None of these 
modifications were observed, when another small HSP (HSPB1), also expressed 
in MCF-7 cells, was downregulated. In conclusion, our data suggest that HSPB8 is 
involved in the mechanisms that regulate cell cycle and cell migration in MCF-7 cells.
INTRODUCTION
Breast cancer (BC) is the most frequent cause of 
cancer death in women in underdeveloped countries, while 
in western countries is the second cause of death, after 
lung cancer [1]. About 70% of cases positive for estrogen 
receptors (ERs) expression, and patients with ER-positive 
BC generally receive anti-hormonal therapy, mainly based 
on anti-estrogens, selective ER modulators (SERMs), or 
inhibitors of aromatase, which sinthesizes estrogens. 
The SERMs are natural or synthetic compounds which 
bind ERs and display tissue specific mixed agonistic-
antagonistic activities [2]. Some SERMs have been 
approved for BC treatment (e.g.: tamoxifen, raloxifen) 
[3], while others, such as some natural phytoestrogens, 
might have a chemo preventive activity [4], an aspect still 
largely debated [5, 6]. The SERMs mechanism of action 
depends on three interdependent factors: the level of ER 
isoform (ERα or ERβ) expression in a given target tissue, 
the different conformational changes of ERs induced 
by a given SERM and the binding of transcriptional 
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regulatory proteins to ERs. In several cases, BC cells 
become resistant to these anti-hormonal therapies [7], 
giving rise to more aggressive tumors (e.g. tamoxifen-
resistant BC). It has been recently proposed that the 
mechanism responsible for anti-hormonal resistance in 
BC is facilitated by autophagy [8], a process responsible 
for the degradation of damaged proteins or organelles [9]. 
In cancer cells, autophagy may have a suppressive activity 
in the initial phase of the tumor growth, while in later 
stages, autophagy may enhance cancer cells survival. In 
several tumors, autophagy involves the small heat shock 
proteins HSPB8 (also known as HSP22, E2IG1, small 
stress protein 1 or H11), an autophagic flux enhancer that 
acts in conjunction with BAG3 [10–13], HSPA8/HSC70 
and STUB1/CHIP to target cargoes to autophagosomes 
(Cristofani et al., in press; [14, 15]), and their recognition 
by SQSTM1/p62 [14]. In stressful conditions (e.g.: 
hypoxia or nutrient deprivation), HSPB8 is upregulated 
[16], and by facilitating autophagy, mediates amino acids 
recycle enhancing cancer cell capability to survive under 
unfavorable conditions. HSPB8-BAG3 complex also 
recognizes damaged cytoskeletal proteins, determining 
their selective degradation by autophagy [17]. Moreover, 
the complex regulates actin dynamic modulation during 
mitosis by influencing spindle orientation required for 
chromosomes alignment at the metaphase plate and 
chromosome segregation [18]. HSPB8 or BAG3 silencing 
results in disorganization of actin-rich retraction fibers and 
alters spindle orientation: HSPB8-BAG3 complex may 
thus mediated quality control mechanism during mitotic 
processes activated in proliferating cells [18].
HSPB8 activity in cancer cells is rather complex. 
HSPB8 is highly expressed in non-endocrine tumors [19, 
20], in which it generally reduces cell proliferation and/or 
induces apoptosis. In other tumors (melanomas, prostate 
cancer (PC), Ewing’s sarcoma and leukemia), HSPB8 
gene is methylated and poorly expressed [21, 22]. Using 
gene array on laser capture microdissection (LCM) of 
tumors from transgenic erbB2, ras, and cyclin D1 mice, 
HSPB8 expression was found to be higher in invasive 
lesions than in preinvasive lesions [23]. A similar pattern 
was observed in LCM from human ductal carcinoma 
[23]. When exogenously expressed in these tumors, 
HSPB8 activates caspase-3 cleavage and apoptosis [19, 
22]. Surprisingly, in other tumor types HSPB8 expression 
correlates with increased aggressiveness [24, 25]. HSPB8 
is highly expressed in BC tumors, particularly in the ER-
positive tumors [26, 27], and in cell lines of hormone-
resistant BC, suggesting its involvement in the acquisition 
of resistance to hormone therapy [28]. HSPB8 is induced 
by estrogens and cadmium (a metalloestrogen) in the ER-
positive BC MCF-7 cells [25], a process reverted by the 
pure anti-estrogen ICI182.780 (faslodex, fulvestrant). 
Instead, the SERM tamoxifen had no effects on HSPB8 
[25], but HSPB8 is highly overexpressed in tamoxifen-
resistant BC (MCF-7) cell subclones [28], possibly 
favouring appearance of drug-resistance in cancer cells 
[28, 29]. Similarly, in multiple myeloma (MM), the 
chemotherapic bortezomib (Velcade, a UPS inhibitor) 
induces the development of bortezomib-resistant cells, in 
which HSPB8 is robustly overexpressed [24].
Here, we evaluated the role of HSPB8 in 
proliferation, cell cycle modification and cell migration of 
cultured human BC cells, and its possible modulation by 
selected SERMs. We also analysed the effects of either 
overexpression or downregulation of HSPB8 during 
concomitant treatments with different SERMs. We found 
that the increased proliferation induced by all SERMs was 
reduced by the concomitant downregulation of HSPB8, 
which led to cell cycle arrest in the G0/G1 phase and 
reduced the migratory ability of MCF-7 cells.
RESULTS
Expression of HSPB8 in different cell types
To assess the potential role of HSPB8 in BC cells, 
we initially compared its expression level in MCF-7 cells 
with that of other highly proliferating tumor cells and with 
undifferentiated induced pluripotent stem cells (iPCSs), 
maintaining cells plated in basal growth condition for 4 
days, before they reached confluency. Expression analysis 
performed using real-time RT-PCR showed that HSPB8 
mRNA is highly expressed in iPSCs, in BC cells (MCF-
7) and in hepatocellular carcinoma (HepG2), while its 
expression is much lower in prostate cancer (PC) cells 
(PC3 and DU145 cells) and in melanoma cells (BML) 
(Figure 1, panel A). When HSPB8 protein levels were 
quantified in Western blot analysis (Figure 1, panel B), we 
found that MCF-7 cells were characterized by very high 
content of HSPB8 as compared to the other cell clones 
selected. We next evaluated HSPB8 expression in other 
BC cell lines and its possible modulation by 17β-estradiol. 
By analysing MCF-7, MDA-MB-231 and T47D BC cell 
lines, we found that in T47D cells HSPB8 is expressed 
at lower levels compared to MCF-7 cells; HSPB8 is 
poorly expressed in MDA-MB-231. 17β-estradiol further 
increased HSPB8 mRNA expression levels in MCF-7 and 
T47D cells, but not in MDA-MB-231 cell line (Figure 1, 
panel C). These data were also confirmed at protein levels 
(Figure 1, panel D).
Effects of SERMs on MCF-7 and MDA-MB-231 
cell growth
We selected specific estrogens and SERMs to 
evaluate their capability to modulate MCF-7 and MDA-
MB-231 cell proliferation, under growing conditions. We 
used 17β-estradiol and estradiol valerate at 10nM doses, 
3β-Adiol, the natural phytoestrogen genistein, raloxifen 
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Figure 1: Expression of HSPB8 in different human cell lines. HSPB8 mRNA and protein levels were measured by real-time 
RT-PCR analysis A. and Western blot analysis B. in iPSCs, PC3, DU145, MCF-7, HepG2 and BLM cell lines. iPSCs: induced pluripotent 
stem cells; PC3 and DU145: prostate cancer cells; MCF-7: breast cancer cells; HepG2: hepatocellular carcinoma; BLM: melanoma cells. 
HSPB8 mRNA and protein levels were measured by real-time RT-PCR analysis C. and Western blot analysis D. in three different human 
breast cancer cell lines treated or not for two days with 17β-estradiol (10nM): MCF7; MDA-MB-231 and T47D. *p<0.05 vs MCF-7 cells 
without treatment (first column). Values represent the mean from three independent experiments.
and tamoxifen at 1μM concentrations. We thus performed 
a MTT assay to measure MCF-7 and MDA-MB-231 cell 
proliferation/viability. Growth analysis revealed that 
proliferation of MCF-7 cells was significantly increased 
after 2 days of treatment with all estrogenic compounds 
tested, including genistein (Figure 2, panel A). The 
most potent activity was associated to estradiol valerate, 
which almost doubled the proliferation/viability of MCF-
7 cells (Figure 2, panel A). As expected, both raloxifen 
and tamoxifen, used as controls, were unable to modify 
the proliferation/viability rate of MCF-7 cells (Figure 2, 
panel A). On the contrary, 2 days treatment with all the 
considered SERMs did not modify MDA-MB-231 cell 
growth (Figure 2, panel B).
Effects of SERMs on the endogenous HSPB8 
expression in MCF-7 cells
We next evaluated whether the drugs could also 
further increase the already high levels of HSPB8 in MCF-
7 cells. HSPB8 mRNA and protein levels were analysed 
in MCF-7 cells treated for 48 hrs with selected active 
dose (based for each compound on their relative Kd for 
ERs). In particular, we used 17β-estradiol and estradiol 
valerate at 10nM concentrations, 3β-Adiol, genistein, 
raloxifen and tamoxifen at 1μM concentrations. HSPB8 
mRNA evaluated in real-time RT-PCR analysis (Figure 
3, panel A) demonstrated that both estradiol (and its 
valerate form, which both bind equally the two ERs [5, 
30–34]) and 3β-Adiol (which binds preferentially ERβ 
exerting agonistic activity) [6, 35] were able to induce 
a robust increase of HSPB8 expression in MCF-7 cells. 
Surprisingly, genistein, which acts as a natural SERM 
(with ERβ preferential binding and agonistic activities 
[36]) did not significantly modify HSPB8 expression. 
The synthetic SERM raloxifene (characterized by a poor 
antiestrogenic activity) was also unable to induce HSPB8 
expression, while, the other synthetic SERM selected, 
tamoxifen (which is considered a potent ER antagonist in 
BC cells) induced two-fold HSPB8 expression (Figure 3, 
panel A). Similar results were observed at protein levels. 
In fact, Western blot analysis (Figure 3, panel B) showed 
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that HSPB8 protein levels are increased by the treatment 
with estradiol (and its valerate form) and by 3β-Adiol. All 
SERMs (natural or synthetic, including tamoxifen) were 
unable to alter HSPB8 protein levels in MCF-7 cells. The 
induction of HSPB8 mRNA and protein levels observed 
using real-time RT-PCR and Western blot analyses were 
further confirmed by immunofluorescence analysis on 
MCF-7 cells treated with 17β-estradiol and 3β-Adiol. An 
intense increase of HSPB8 immunoreactivity was found 
after exposure to 17β-estradiol, 3β-Adiol; a slight increase 
was observed in cells treated with genistein (Figure 3, 
panel C).
HSPB8 silencing in MCF-7 cell line and its effect 
on ERα and ERβ expression
In order to evaluate whether HSPB8 is essential 
for BC cells dynamics, we designed specific siRNA 
to silence the expression of HSPB8. To produce and 
characterize HSPB8 knock-down cell models, MCF-
7 cells were transfected with the designed siRNA-
HSPB8 and analysed at different times (from 1 up to 5 
days) after transfection. Using RealTime RT-PCR, we 
first evaluated HSPB8 mRNA levels. Figure 4, panel 
A shows that a significant reduction of HSPB8 mRNA 
levels was already detectable 1 day after transfection; 
HSPB8 silencing was complete 3 days lasting up to 
5 days after transfection. When we analysed HSPB8 
protein levels in Western blot analysis (Figure 4, panel 
B) we observed an identical trend of reduction to that 
found for mRNA levels, proving that HSPB8 silencing 
was very efficient in MCF-7 cells with the selected 
siRNA. The downregulation of HSPB8 mRNA and 
protein levels observed by RealTime RT-PCR and 
Western blot analyses (Figure 4, panel A and B) were 
further confirmed by immunofluorescence analysis using 
a specific anti-HSPB8 antibody. In fact, in MCF-7 cells 
treated with siRNA-HSPB8, we observed an almost 
complete disappearance of HSPB8 immunoreactivity 
after 48 hours of siRNA treatment (Figure 4, panel C).
To assess whether HSPB8 silencing was able 
to alter estrogenic responsiveness of MCF-7 cells, we 
analysed ERα and ERβ mRNA levels 1, 2, and 3 days after 
transfection of siRNA-HSPB8. Neither the expression of 
ERα (Figure 4, panel D), nor that of ERβ (Figure 4, panel 
E) were affected by HSPB8 silencing. However, while 
the levels of ERα remained very similar in all samples 
analysed, we observed large variations of ERβ expression, 
even if these modifications never reached statistical 
significance. These alterations could be due to a rather 
marked fluctuation of the ERβ levels in MCF-7 cells in 
basal conditions.
To assess whether other HSPBs were expressed 
in MCF-7 cells, we initially quantified by Western blot 
analysis the protein levels of four different small heath 
shock proteins: HSPB1, HSPB2, HSPB3 and HSPB5. 
We found that MCF-7 cells expressed high levels of 
HSPB1, while HSPB2, HSPB3 and HSPB5 were not 
detectable (Figure 4, panel F). In order to compare the 
activity of these two HSPBs expressed in BC cells, we 
analysed whether HSPB1 downregulation recapitulates the 
modification we described after HSPB8 silencing: To this 
aim, we produced a siRNA directed against HSPB1 and 
transfected MCF-7 cells to evaluate HSPB1 protein levels. 
We found that HSPB1 protein levels were significantly 
reduced 3 days after transfection (Figure 4, panel G); and 
totally abolished 5 days after transfection, proving that 
HSPB1 silencing was very efficient in MCF-7 cells with 
the selected siRNA.
Figure 2: Cellular proliferation of MCF-7 and MDA-MB-231 cell lines. MCF-7 A. and MDA-MB-231 B. cellular proliferation 
was evaluated by MTT assay 2 days after treatment with DMSO (Control), 17β-estradiol (10nM), estradiol valerate (10nM), 3β-Adiol 
(1μM), genistein (1μM), raloxifen (1μM) and tamoxifen (1μM). Statistical analysis was performed by one-way ANOVA followed by 
Bonferroni multiple comparison tests. *p<0.05 vs Control. Values represent the mean from three independent experiments. C. Control cells; 
E: 17β-estradiol; EV: estradiol valerate; 3β: 3β-Adiol; Gen: genistein; Ral: raloxifen; Tam: tamoxifen.
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Effects of HSPBs silencing on MCF-7 cell cycle 
progression
On the basis of these data and on the recently 
described involvement of HSPB8 in the control of spindle 
orientation during mitosis [18], we next analysed if HSPB8 
and HSPB1 silencing in MCF-7 could affect the cell cycle 
progression. We depleted HSPB8 and HSPB1 by siRNA 
transfection and, three days after transfection, we analyzed 
the distribution of MCF-7 cells through the cell cycle 
by FACS analysis. HSPB8 silencing correlated with a 
considerable increase of cell number resting in the G0/G1 
phase (control, 64.10%; siRNA-HSPB8 81.24%), while the 
number of cells progressing in the S phase was remarkably 
decreased (control, 9.63%; siRNA-HSPB8 3.94%). In the 
G2/M cell cycle phase the number of HSPB8 silenced 
cells was diminished about 50% (control, 21.91%; siRNA-
HSPB8, 10.98) (Figure 5, panels A and B). On the contrary, 
HSPB1 silencing did not modify neither the number of 
cells resting in the G0/G1 phase (control, 51.93%; siRNA-
Figure 3: Expression of HSPB8 in MCF-7 cell line. HSPB8 mRNA and protein levels were quantified by real-time RT-PCR analysis 
A. and Western blot analysis B. 2 days after treatment with DMSO (Control), 17β-estradiol (10nM), estradiol valerate (10nM), 3β-Adiol 
(1μM), genistein (1μM), raloxifen (1μM) and tamoxifen (1μM). Statistical analysis was performed by one-way ANOVA followed by 
Bonferroni multiple comparison tests. Representative pictures of immunofluorescence staining of HSPB8 (red, anti-rabbit) and α-tubulin 
(green, anti-mouse) in MCF-7 cells, treated as above for 2 days. DAPI (blue) was used to stain DNA C. *p<0.05 vs Control. Values 
represent the mean from three independent experiments. C. Control cells; E: 17β-estradiol; EV: estradiol valerate; 3β: 3β-Adiol; Gen: 
genistein; Ral: raloxifen; Tam: tamoxifen.
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HSPB1 50.24%), nor the number of cells progressing in 
the S phase (control, 14.22%; siRNA-HSPB1 14.11%). In 
the G2/M cell cycle phase the number of HSPB1 silenced 
cells was slightly diminished (control, 30.27%; siRNA-
HSPB1, 29.95%) (Figure 5, panel C and D).
To overexpress HSPB8, MCF-7 cells were 
transfected with control vector or with pCI-NEO-HSPB8 
plasmid and analysed three days after transfection. The 
results indicated that HSPB8 overexpression correlated 
with a small reduction in the number of cells resting in 
G0/G1 phase (pCI-NEO-HSPB8, 63.64%; empty vector, 
68.33%), while the population of cells progressing at the 
S phase was essentially unchanged (pCI-NEO-HSPB8, 
7.53%; empty vector, 7.66%). Furthermore, HSPB8 
overexpression induced a small increase in the number 
of cells accumulated in G2/M phases (19.17%) when 
compared to control cells (17.06%) (Figure 5, panel E and 
F). These data suggest that HSPB8 silencing induced cell 
cycle arrest in the G0/G1 phase of MCF-7 cells, while its 
overexpression did not alter their cell cycle distribution. 
Furthermore, to demonstrate overexpression efficiency of 
HSPB8, we transfected MCF-7 cells with control vector 
or pCI-NEO-HSPB8 plasmid to enhance HSPB8 levels at 
different times (from 1 up to 3 days) after transfection. 
Using Western blot analysis, we observed that there was 
a significantly increase of HSPB8 protein levels one day 
after transfection (Figure 5, panel G). HSPB8 protein 
levels remain elevated up to 3 days after transfection, 
proving that HSPB8 overexpression was very efficient in 
MCF-7 cells.
Effects of HSPB8 overexpression on MDA-
MB-231 cell cycle progression
We next analysed the effects of HSPB8 
overexpression in MDA-MB-231 cell cycle progression. 
We observed that HSPB8 overexpression in MDA-
MB-231 cells correlated with a small decrease in the 
number of cells resting in G0/G1 phase (pCI-NEO-
HSPB8, 66.94%; empty vector, 69.45%); in the same 
way, the population of cells progressing at the S phase 
was slightly increased (pCI-NEO-HSPB8, 13.08%; empty 
vector, 10.13%). Furthermore, HSPB8 overexpression 
induced a weakly increase in the number of cells 
accumulated in G2/M phases (12.24%) when compared 
to control cells (8.35%) (Figure 6, panel A and B). These 
data suggest that HSPB8 overexpression did not alter the 
MDA-MB-231 cell cycle distribution.
Figure 4: HSPB8 silencing and its effect on expression of ERα and ERβin MCF-7 cell line. MCF-7 cells were transfected 
with siRNA-HSPB8 or NT-siRNA and the analysis was performed 1, 2, 3, 4 and 5 days after transfection. The HSPB8 mRNA and protein 
levels were measured by real-time RT-PCR A. and Western blot analysis B. Statistical analysis was performed by one-way ANOVA followed 
by Bonferroni multiple comparison tests *p<0.05 vs Control-1day (untransfected cells). Representative pictures of immunofluorescence 
staining of HSPB8 (red, anti-rabbit) and α-tubulin (green, anti-mouse) in MCF-7 cells transfected for 1 and 2 days. DAPI (blue) was used 
to stain DNA C. NT = Non-targeting. ERα D. and ERβ E. mRNA levels were measured by real-time RT-PCR analysis 1, 2, and 3 days after 
transfection. Values represent the mean from three independent experiments, no statistical differences were observed. The expression of 
different small heat shock protein was evaluated by Western blot analysis in MCF-7 cell line F. MCF-7 cells were transfected with siRNA-
HSPB1 or NT-siRNA and HSPB1 protein levels were measured by Western blot analysis 3, 4 and 5 days after transfection G. Statistical 
analysis was performed by one-way ANOVA followed by Bonferroni multiple comparison tests *p<0.05 vs Control-1day (untransfected 
cells).
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Figure 5: FACScan analysis of MCF-7 cells. The adherent MCF-7 cells were treated with transfection medium (Control-1 and -2) 
A-C. transfected with siRNA-HSPB8 B., with siRNA-HSPB1 D., with empty vector as control E. and with plasmid pCI-NEO-HSPB8 
that contains the sequence of human HSPB8 cloned in pCI F. After 3 days, the cells were measured on a FACScan flow cytometer with an 
argon laser at 488 nm for excitation and analyzed using Cell Quest software. Each experiment was performed in triplicate. The efficiency 
of HSPB8 overexpression in MCF-7 cells was evaluated by Western blot analysis, 1, 2 and 3 days after transfection G. Statistical analysis 
was performed by one-way ANOVA followed by Bonferroni multiple comparison tests *p<0.05 vs Control-1day (untransfected cells); EV 
empty vector.
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Effects of HSPBs silencing and SERMs 
treatment on MCF-7 cell growth and migration
In order to study the role of HSPB8 and HSPB1 in 
the regulation of MCF-7 cell growth, we evaluated cellular 
proliferation by MTT assay 1, 4 and 5 days after HSPB8 
and HSPB1 silencing. As shown in Figure 7, panel A, 
HSPB8 silencing correlated with a robust and significant 
decrease of MCF-7 cell growth when compared to control 
cells, while HSPB1 silencing did not alter MCF-7 cellular 
proliferation (Figure 7, panel B).
Next, MCF-7 cells were transfected or not with 
siRNA-HSPB8 and simultaneously treated for 2 days 
with vehicle (DMSO) or with 17β-estradiol, 3β-Adiol 
and genistein. Figure 7, panel C, shows that, as expected, 
17β-estradiol induced a significant increase of MCF-
7 cellular proliferation, but this estrogenic activity 
was significantly reduced 4 and 5 days after HSPB8 
silencing. In the same manner, the growth of MCF-7 
cells was significantly increased after 2 days of treatment 
with 3β-Adiol with respect to control cells (Figure 7, 
panel D), and this pro-proliferative effect appeared to 
be significantly diminished following HSPB8 silencing. 
Further, exposure to 1μM genistein increased MCF-7 cell 
proliferation, with a significant gain in the number of cells 
compared to untreated cells (Figure 7, panel E). Even in 
this case, the increased proliferation induced by genistein 
was reduced after HSPB8 silencing. These results suggest 
that the presence of HSPB8 is required for a proper 
estrogen-induced MCF-7 cell proliferation.
Then, we studied the impact of HSPB8 depletion on 
cell migration. Haptotaxis was evaluated in a Boyden’s 
chamber using laminin coated membranes, because 
preliminary experiments had indicated that MCF-7 cells 
fail to migrate in the absence of a specific substrate (data 
not shown). MCF7 cells were transfected or not with 
siRNA-HSPB8 and simultaneously treated for 2 days 
with vehicle (DMSO) or with 17β-estradiol, 3β-Adiol 
and genistein. HSPB8 silencing significantly reduced the 
percentage of migrating cells as compared to non-silenced 
cells (Figure 7, panel F). 17β-estradiol significantly 
increased the percentage of migrating cells with respect 
to control cells, indicating that 17β-estradiol has a pro-
migratory activity on MCF-7 cells; this pro-migratory 
effect was significantly reduced by HSPB8 silencing 
(Figure 7, panel F). On the contrary, 3β-Adiol significantly 
reduced the percentage of migrating cells compared to 
DMSO-treated cells, indicating that, despite of being an 
Figure 6: FACScan analysis of MDA-MB-231 cells. MDA-MB-231 cells were transfected with empty vector as control A. and 
with plasmid pCI-NEO-HSPB8 that contains the sequence of human HSPB8 cloned in pCI B. After 3 days, the cells were measured on a 
FACScan flow cytometer with an argon laser at 488 nm for excitation and analyzed using Cell Quest software.
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Figure 7: MCF-7 cells proliferation and migration. MCF-7 cells were transfected with siRNA-HSPB8 A. or siRNA-HSPB1 B. and 
cellular proliferation was evaluated by MTT assay 1, 4 and 5 days after transfection. MCF-7 cells were transfected with siRNA-HSPB8 and 
treated for 5 days after transfection with 10nM 17β-estradiol C. 1μM 3β-Adiol D. and 1μM genistein E. Control: cells untransfected and 
treated with DMSO. Cellular proliferation was evaluated 1, 2, 3, 4 and 5 days after transfection. Statistical analysis was performed by two-
way ANOVA followed by Bonferroni multiple comparison tests. Values represent the mean from three independent experiments. *p<0.01vs 
Control; #p<0.01 17β-estradiol vs siRNA-HSPB8+17β-estradiol; §p<0.01 3β-Adiol vs siRNA-HSPB8+3β-Adiol; $p<0.01 genistein vs 
siRNA-HSPB8+genistein. For the migration assay, MCF-7 untransfected cells were treated for 2 days with DMSO (first column), while 
the cells transfected with siRNA-HSPB8 were treated for 2 days after transfection with DMSO (second column), or with 17β-estradiol 
(E, 10nM), 3β-Adiol (3β, 1μM) and genistein (Gen, 1μM). Cells were then detached, and transferred to Boyden’s Chamber F. Statistical 
analysis was performed by one-way ANOVA followed by Bonferroni multiple comparison tests. Values represent the mean from three 
independent experiments. *p<0.05 vs untransfected cells (first column); #p<0.05 vs 17β-estradiol.
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estrogenic compound, 3β-Adiol has anti-migratory effect 
on MCF-7 cells, and it may be a physiological antagonist 
of 17β-estradiol. In the same manner, the exposure to 
genistein inhibited the migratory activity of MCF-7 
cells; thus, like 3β-Adiol, also these natural SERMs has 
an opposite effect than 17β-estradiol on MCF-7 cell 
migration, which is not influenced by HSPB8 silencing.
Interestingly, in BC cells, autophagy is modulated 
through cell cycle arrest [37]. Moreover, interplay between 
autophagy and cell cycle regulation in the inhibition of 
cancer cell proliferation has been well documented [38]. 
We thus investigated whether changes in the expression 
levels of HSPB8, which affects cell cycle in MCF-7 cells, 
also alter autophagy. As shown in Supplementary Figure 
S1 there were no variations in different autophagy markers 
(LC3, SQSTM1/p62, TFEB and ZK-SCAN3).
DISCUSSION
BC is a very common and heterogeneous disease, 
which too often becomes resistant to endocrine therapy. 
The mechanisms behind this resistance to treatment 
are still poorly understood. The enhanced capability of 
cancer cells to respond to different types of cell stress 
(or stress tolerance) is emerging as one of the factors that 
may confer resistance to chemotherapy [28, 29]. Stress 
tolerance is generally mediated by an increased function of 
the PQC system, and particularly of selected chaperones 
and of autophagy [28]. The chaperone HSPB8 enhances 
autophagic flux, thereby acting as a potent facilitator of the 
autophagic process [14, 15, 39, 40], and it has been found 
increased in tamoxifen-resistant BC cells [28].
Here, we analysed the involvement of HSPB8 in BC 
cell dynamics. We initially characterized human BC cells 
and found that triple-positive hormone-sensitive MCF-7 
cells (but not triple negative MDA-MB-231) express very 
high mRNA and protein levels of HSPB8. MCF-7 cells 
also express HSPB1, but not HSPB2, HSPB3 or HSPB5. 
We then evaluated the effects of SERMs on HSPB8 
expression and possible modulation of cell viability. We 
found a significant increase of MCF-7 cells viability 
exposed to estrogenic (particularly estradiol valerate) 
compounds, while the SERMs tamoxifen and raloxifen did 
not modify cell viability. Interestingly, genistein treatment 
resulted in a proliferative rather than anti-proliferative 
effect on MCF-7 cells. In agreement with previous data 
[23, 25], estradiol enhanced HSPB8 expression. Moreover, 
we found that some SERMs (synthetic like tamoxifen, 
and natural like 3β-Adiol), but not all SERMs (synthetic 
like raloxifen, and natural like genistein) induced HSPB8 
mRNA and protein. Interestingly, HSPB8 silencing in 
MCF-7 cells did not affect ERs expression (neither ERα 
nor ERβ).
Since HSPB8 controls spindle orientation during 
mitosis [18], thus affecting cell cycle progression, we 
analyzed whether modulation of HSPB8 in MCF-7 would 
influence the cell cycle. We found that while HSPB8 over-
expression did not modify the distribution of MCF-7 cells 
in the various phases of the cell cycle, HSPB8 silencing 
correlated with an increased number of cells resting in 
the G0/G1 phase, thus possibly reducing the ability of the 
cells to pass through the restriction point. These effects 
were specific for HSPB8, since HSPB1 downregulation 
did not alter cell distribution in the various phases of the 
cell cycle. These data extend some previous reports [23, 
41] that proposed HSPB8 as a target associated with ER-
positive tumors and cyclin D1, one of the key regulators of 
the cell cycle. In addition, we found that HSPB8 (but not 
HSPB1) silencing resulted in a great reduction of MCF-
7 cell proliferation, even in presence of 17β-estradiol, 
which is a potent inducer of MCF-7 cellular proliferation. 
In the same manner, MCF-7 cell growth was significantly 
increased by 3β-Adiol and genistein treatment, and 
these pro-proliferative effects appeared to be partially 
diminished following HSPB8 silencing. Therefore, 
based on our results, we conclude that HSPB8 positively 
modulates MCF-7 cell growth.
Notably HSPB8 also has an impact on cell 
migration. Indeed HSPB8 down-regulation combined 
with exposure to SERMs modulated the migratory ability 
of MCF-7 cells, since while 17β-estradiol increased 
migration, this pro-migratory effect was abolished by 
HSPB8 silencing. The pro-migratory activity of HSPB8 
in cancer cells migration has also been described in 
ovarian cancer (SKOV3.ip1) cells in which it was 
demonstrated that HSPB8 acts as a positive regulator in 
TGF-β -induced migration of ovarian cancer cells and 
directs ovarian cancer toward progression; as expected, 
HSPB8 silencing had the opposite effects in these cells 
[42]. In our study we found that 3β-Adiol exerted an anti-
migratory effect on MCF-7 cells maintained by HSPB8 
silencing. Thus, similarly to PC cells [6, 35, 43], also 
in BC cells, estradiol and 3β-Adiol act as physiological 
antagonists on cell migration and differentially synergize 
with HSPB8. Omoto and Iwase [44] argued that the anti-
migratory effects of 3β-Adiol are due to a preferential 
interaction of 3β-Adiol with ERβ that determines an 
inhibition of BC cell migration [43]. Also genistein 
exerted an anti-migratory activity, but in this case HSPB8 
silencing did not influence the overall effect of genistein 
on cell migration. Notably, while some studies argue 
that genistein in BC cells is able to induce apoptosis, 
inhibits cell differentiation and inhibits angiogenesis 
[45–48], others suggest that genistein increases the 
metabolic activity in MCF-7 cells, thus enhancing growth 
and development of the tumor and ability to generate 
metastases [49, 50]. Based on preclinical data, Kwon [51] 
suggested that high concentration of genistein effectively 
inhibited the growth of BC cells regardless of their ER 
status. However, genistein at low concentration oppositely 
stimulated ER-positive breast tumors [51], and thus the 
potential of genistein in BC remains still largely debated.
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In conclusion, the data here reported suggest that 
HSPB8 is involved in the mechanisms that regulate cell 
cycle and in those involved in cell migration. Although 
the data reported in this study provide the basis for 
advancing concrete hypotheses about the role played by 
HSPB8 in BC, further studies are needed to better clarify 
the molecular mechanisms that underlie its activities and 
the possibility of its eventual use as a therapeutic target.
MATERIALS AND METHODS
Cell culture and treatments
MCF-7, MDA-MB-231, T47D, DU145, PC3 
and HepG2 cell lines were originally obtained from the 
American Type Culture Collection (Rockville, MD). Cells 
were routinely grown in RPMI 1640 medium (Biochrom 
KG, Berlin, Germany), supplemented with 5% foetal 
bovine serum (FBS) that was obtained from GIBCO 
(GIBCO, BRL, Grand Island, NY), glutamine (1mM) and 
antibiotics (100 IU/ml, penicillin G sodium and 100 μg/ml 
streptomycin sulphate) in a humidified atmosphere of 5% 
CO2, 95% air at 37°C.
HepG2 cells were cultured in MEM medium 
supplemented with 10% FBS, glutamine and antibiotics 
as described above.
The human BLM (NRAS-mutant, BRAF-wild 
type) melanoma cell line was provided by Dr. G.N. van 
Muijen (Department of Pathology, Radbound University 
Nijmegen Medical Center, Nijmegen, The Netherlands). 
This cell line is a subline of BRO melanoma cells isolated 
from lung metastases after subcutaneous inoculation of 
nude mice with BRO cells [52]. BLM cells were routinely 
cultured in DMEM medium supplemented with 10% FBS, 
glutamine and antibiotics as described above.
iPSC cells were obtained from fibroblast of healthy 
donor (P6-2 clone) and generated by Oct4, Klf4, Sox2 and 
c-Myc transfection. They were kindly provided by Dr. 
Christopher Grunseich and Dr. Kennet Fischbeck, NIH, 
Bethesda, MD, USA [53]. iPSC cells were cultured in 
Essential 8 medium (Life Technologies).
In all the experiments MCF-7, T47D and MDA-
MB-231 cells were grown in RPMI medium supplemented 
with 5% FBS. At the starting of the experiment, for 
synchronizing cell growth, the medium was replaced with 
RPMI 1640 without FBS and without phenol red, in which 
the cells were kept overnight. During this time period, 
cell growth slowed down. The day after, the medium was 
one more time replaced with RPMI 1640 without phenol 
red containing 5% charcoal-treated FBS (E2-deficient 
medium).
Reagents
17β-estradiol, estradiol valerate and genistein were 
from Sigma-Aldrich (St. Louis, MO, USA). 3β-Adiol was 
from Steraloids (London, UK); raloxifen and tamoxifen 
were kindly obtained from Siena Biotech (Siena, Italy).
Plasmids and siRNA
The plasmid pCI-NEO-HSPB8 contains the 
sequence of human HSPB8 cloned in pCI (Promega, 
Madison, WI, USA) [54]; an empty vector was used as 
control. To silence endogenous HSPB8 expression, we 
used a custom siRNA duplex (CGG AAG AGC UGA UGG 
UAA AUU, Dharmacon, Thermo Scientific Life Sciences 
Research, Waltham, MA, USA); to silence endogenous 
HSPB1 we used a SMARTpool: ON-TARGETplus 
HSPB1 siRNA (L-005269-00-0005, Dharmacon, USA); a 
Non-Targeting siRNA (NT) was used as negative control 
(UAG CGA CUA AAC ACA UCA A, Catalog Item 
D-001210-01-05, Dharmacon, USA).
All plasmids were transfected using Jet-Prime 
Transfection Reagent and Jet-Prime Buffer (Kit Polyplus, 
Polyplus-transfection® SA New York, NY, USA), 
according to the manufacturers' instructions.
mRNA expression analysis
MCF-7 cells were seeded in 6-well plates at 
300,000 cells/well, transfected and/or 1 day later treated 
for 2 days with 17β-estradiol (10nM), estradiol valerate 
(10nM), 3β-Adiol (1μM), genistein (1μM) raloxifen 
(1μM) and tamoxifen (1μM). 3 days after transfection, 
cells were harvested in 4M guanidium-isothiocyanate 
(containing 25mM sodium citrate pH 7.5, 0.5% sarcosyl 
and 0.1% 2-mercaptoethanol) and total RNA was isolated 
using phenol-chloroform extraction method [55]. RNA 
quantification was carried out by absorption at 260 nm. 
Total RNA (1μg) was treated with DNAse and reverse 
transcribed into cDNA using the High-Capacity cDNA 
Archive Kit (Applied Biosystems, Life Technologies 
Corporation) according to the manufacturer's protocol. 
Primers for real-time PCR recognising HSPB8, LC3, 
SQSTM1/p62, TFEB and RPLP0 mRNAs were 
previously described [56]. Primers for real-time PCR of 
the ERα, ERβ, ZK-SCAN3 and 18S were designed in 
accordance with recommendations accompanying the 
CFX 96 Real Time System (Bio-Rad, Hercules, CA, 
USA) on C-G base content and using the program Primer 
Express 3. Primers were synthetized by MWG Biotech 
(Ebersberg, Germany) with the following sequence: ERα 
upstream primer, 5'-CGGTTCCGCATGATGAACCT-3' 
and ERα downstream primer, 5'- TGGTCCTTCTC 
TTCCAGAGACTTC-3'; ERβ upstream primer, 
5'-AGCTGGCTGACAAGGAACTG-3' and ERβ 
downstream primer, 5'- CAGGCTGAGCTCCACAA 
AGC-3'; ZK-SCAN3 upstream primer, 
5'-GATGGAAAGCCAGTTGGAAA-3' and ZK-SCAN3 
downstream primer, 5'-AAATTCGGGTGAAGCCT 
TTT-3' 18S upstream primer, 5'-GGATGTAAAGGAT 
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GGAAAATACA-3' and 18S downstream primer, 5'- 
TCCAGGTCTTCACGGAGCTTGTT -3'. The evaluated 
efficiency of each set of primers was close to 100% for 
target and reference genes. Real-Time PCR was performed 
using the CFX 96 Real Time System (Bio-Rad) in 10μL 
total volume, using the iTaq SYBR Green Supermix (Bio-
Rad), and with 500nM primers. PCR cycling conditions 
were as follows: 94°C for 10 minutes, 35 cycles at 94°C 
for 15 seconds and 60°C for 1 minute. Melting curve 
analysis was always performed at the end of each PCR 
assay as a control for specificity. Data were expressed as 
Ct values and used for the relative quantification of targets 
using the ΔΔCt calculation. To exclude potential bias 
because of averaging, data were transformed using the 
equation 2−ΔΔCt to give N-fold changes in gene expression; 
all statistics were performed with ΔCt values. Each sample 
was analyzed in triplicate (n=3); HSPB8, ERα, ERβ, 
LC3, SQSTM1/p62, TFEB and ZK-SCAN3 values were 
normalized with those of RPLP0.
Western blotting analyses
MCF-7 cells were seeded in 6-well plates at 
300,000 cells/well transfected and/or treated for 2 days 
with 17β-estradiol (10nM), estradiol valerate (10nM), 
3β-Adiol (1μM), genistein (1μM) raloxifen (1μM) and 
tamoxifen (1μM). MCF-7 cells were harvested in RIPA 
buffer addicted with protease inhibitors, centrifuged, and 
washed in PBS. Protein concentration was determined 
using the Bradford assay. Equal amount of protein 
(20μg) were resolved on a 7-15% SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). Proteins were 
transferred using a transfer apparatus (BIO-RAD Trans 
Blot semi-dry). The membrane was washed with 10mM 
Tris-HCl, 150mM NaCl, 0.1% Tween 20 (TBST) for 
30 min, blocked in TBST and 5% (w/v) dry skimmed 
milk, and then incubated with the primary antibody at 
4°C o/n. For HSPB8, HSPB1, HSPB2, HSPB3, HSPB5, 
LC3, SQSTM1/p62, α-tubulin and actin detection we 
used a) rabbit polyclonal antibody against HSPB8 
(kindly provided by Dr. Jacques Landry, Quebec, 
Canada; dilution 1:2000); b) rabbit polyclonal antibody 
against HSPB1 (kindly provided by Dr. Jacques 
Landry, Quebec, Canada; dilution 1:2000); c) mouse 
monoclonal antibody against HSPB2 (SC-136339 Santa 
Cruz Biotechnology; dilution 1:1000); rabbit polyclonal 
antibody aginst HSPB3 (SAB1100972 Sigma-Aldrich; 
dilution 1:1000); d) mouse monoclonal antibody against 
HSPB5 (SMC-159A STRESSMARQ; dilution 1:1000); 
e) rabbit polyclonal antibody against LC3 (L8918, 
Sigma-Aldrich; dilution 1:2500); f) rabbit polyclonal 
antibody against SQSTM1/p62 (ab91526, Abcam; 
dilution 1:1000); g) mouse monoclonal antibody 
against α-tubulin (T 6199, Sigma-Aldrich; dilution 
1:4000); h) goat polyclonal antibody against actin (I-19, 
Santa Cruz Biotechnology; dilution 1:1000). Then, the 
membranes were washed and incubated for 1 hr at room 
temperature with secondary antibody conjugated with 
peroxidase (anti rabbit for HSPB8, HSPB1, HSPB3, 
LC3 and SQSTM1/p62, dilution 1:10,000; anti-goat for 
actin, dilution 1:5000; anti-mouse for HSPB2, HSPB5, 
dilution 1:5000 and α-tubulin, dilution 1:20.000). 
Immunoreactive bands were visualized using the 
enhanced chemiluminescence’s detection kit reagents 
(ClarityTM Western ECL Substrate, Bio-Rad, Italy). A 
ChemiDoc XRS System (Bio-Rad) was used for the 
image acquisition.
Immunofluorescence
MCF-7 cells were plated on 13mm diameter 
coverslips at 40.000 cells/well transfected and/or 
treated with 17β-estradiol (10nM), 3β-Adiol (10μM), 
and genistein (1μM). 2 days after treatments, cells were 
fixed in 4% paraformaldehyde (PFA), permeabilized in 
0.5% Triton X-100 and then, the unspecific sites were 
blocked in 5% fetal bovine serum (Gibco) in PBS. 
Subsequently, cells were incubated with the primary 
antibodies o/n at 4°C. The primary antibodies used 
were: rabbit polyclonal anti-HSPB8 antibody (kindly 
provided by Jacques Landry, Quebec, Canada) 1:200; 
mouse monoclonal anti-α-tubulin antibody (Sigma-
Aldrich) 1:200. Secondary antibodies (Rockland) were 
used at the concentration of 1:500 for 1 hr at room 
temperature: 611-700-127 (red, anti-rabbit) for the 
detection of HSPB8 and 710-702-124 (green, anti-
mouse) for the detection of α-tubulin. The manufacturer 
guarantees the use of these secondary antibodies for 
multiple labelling procedures, since they are purified 
against cross-reactivity to other species. Nuclei were 
stained with DAPI (Sigma-Aldrich). Finally, the cells 
were washed in PBS before mounting using Mowiol 
40-88 (Sigma-Aldrich). Images were collected using the 
UIC-Metavue 6.2.2 (UIC-Crisel Instr. Rome) imaging 
system on an Axiovert Zeiss 200 microscope, utilising a 
40× magnification (NA 0.8) objective.
Cell growth studies
Cells growth/viability was measured by MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. Briefly, culture medium was replaced 
with fresh medium containing MTT (1.5 mg/ ml) and 
the multiwells were incubated at 37°C for 1 hr, then the 
medium was removed and 2-propanol (500μl) was added 
to solubilize the crystals. The absorbance was red at 550 
nm with an Enspire 2300 Multimode Plate Reader (Perkin 
Elmer, Italy).
To study the effect of SERMs on MCF-7 and MDA-
MD-231, cells were seeded in 24-well plates at 40,000 
cells/well, transfected and/or treated for 2 days with 
17β-estradiol (10nM), estradiol valerate (10nM), 3β-Adiol 
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(1μM), genistein (1μM) raloxifen (1μM) and tamoxifen 
(1μM); cell viability was analyzed as described above.
FACScan analysis
For FACScan analysis the adherent MCF-7 and 
MDA-MB-231 cells were seeded in 12-well plates at 
80,000 cells/well. After 24 hrs, cells were transfected 
with 0.5μg of empty vector, 0.5μg of pCI-NEO-HSPB8 
plasmid, 40nM of siRNA-HSPB8 and 50nM of siRNA-
HSPB1 (only for MCF-7 cells); 3 days after transfection, 
cells were washed in PBS, harvested, centrifuged, and re-
suspended in 400μl of Permealization buffer (100mM Tris 
pH 7.4, 150μM NaCl, 1μM CaCl2, 0.5μM MgCl2, 0.1% 
NP-40) addicted with propidium iodide 5μM. Cells were 
incubated at room temperature for 15 min. Cells were then 
measured on a FACScan flow cytometer (FACS Calibur - 
BD Biosciences, San Jose, CA, USA). Cytofluorimetric 
results were analyzed using CellQuest (BD Biosciences) 
analysis software. All the flow cytometric measurements 
were done using the same instrument settings, and at least 
10,000 cells were measured in each sample. The results 
of three separate experiments are presented as the mean ± 
SD. Each experimental group was performed in triplicate.
Haptotaxis assay
Briefly, cell migration assay was performed 
using a 48 well-Boyden chamber (NeuroProbe, Inc., 
Gaithersburg, MD, USA) containing 8μm polycarbonate 
filters (Nucleopore, Concorezzo, Milan, Italy). Filters 
were coated on one side with 50μg/ml laminin, rinsed 
once with PBS, and then placed in contact with the 
lower chamber containing RPMI 1640 medium. MCF-
7 cells, treated with 17β-estradiol (10nM), 3β-Adiol 
(1μM) and genistein (1μM) for 2 days after transfection 
with siRNA-HSPB8, were collected and then added in 
aliquots (75,000 cells/50μl) to the top of each chamber 
and allowed to migrate through coated filters for 4 hrs. 
At the end of the incubation, the migrated cells attached 
on the lower membrane surfaces were fixed, stained with 
Diffquik (Biomap, Italy) and counted in standard optical 
microscopy.
The results of four separate experiments of migration 
are presented as the mean ± SD. Each experimental group 
consisted of 12 samples. The results are expressed as a 
percentage of migrated cells versus control cells.
Statistical analysis
Statistical analysis was performed by one-way 
ANOVA followed by Bonferroni multiple comparison 
tests. *p<0.05 was considered statistically significant.
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